Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2013 2
2014 2
2015 1
2016 4
2017 2
2018 1
2019 3
2020 3
2021 8
2022 3
2023 9
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Schwannomatosis 2"
Page 1
Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Tamura R. Tamura R. Int J Mol Sci. 2021 May 29;22(11):5850. doi: 10.3390/ijms22115850. Int J Mol Sci. 2021. PMID: 34072574 Free PMC article. Review.
There are three types of NF: NF1 accounting for 96% of all cases, NF2 in 3%, and schwannomatosis (SWN) in <1%. The NF1 gene is located on chromosome 17q11.2, which encodes for a tumor suppressor protein, neurofibromin, that functions as a negative regulator of Ra …
There are three types of NF: NF1 accounting for 96% of all cases, NF2 in 3%, and schwannomatosis (SWN) in <1%. The NF1 gene is loc …
A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
Acar S, Nieblas-Bedolla E, Armstrong AE, Hirbe AC. Acar S, et al. Pediatr Neurol. 2022 Sep;134:1-6. doi: 10.1016/j.pediatrneurol.2022.06.003. Epub 2022 Jun 10. Pediatr Neurol. 2022. PMID: 35759947 Free article. Review.
INTRODUCTION: The neurofibromatoses comprise three different genetic conditions causing considerable morbidity and mortality: neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN). This review summarizes recent and ongoing clin …
INTRODUCTION: The neurofibromatoses comprise three different genetic conditions causing considerable morbidity and mortality: neurofibromato …
Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.
Brown R. Brown R. Curr Oncol Rep. 2023 Dec;25(12):1409-1417. doi: 10.1007/s11912-023-01451-z. Epub 2023 Oct 31. Curr Oncol Rep. 2023. PMID: 37906356 Review.
Neurofibromatosis type I (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis represent a diverse group of genetic tumor predisposition syndromes with a shared feature of tumors affecting the peripheral nerve sheaths. ...This article provides an update regardi …
Neurofibromatosis type I (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis represent a diverse group of genetic tumor …
Neurocutaneous Syndromes and Brain Tumors.
Ullrich NJ. Ullrich NJ. J Child Neurol. 2016 Oct;31(12):1399-411. doi: 10.1177/0883073815604220. Epub 2015 Oct 12. J Child Neurol. 2016. PMID: 26459515 Review.
This review outlines the central nervous system tumors associated with underlying neurocutaneous disorders, including neurofibromatosis type 1, neurofibromatosis type 2, schwannomatosis, tuberous sclerosis complex, Von Hippel Lindau, and nevoid basal cell carcinoma …
This review outlines the central nervous system tumors associated with underlying neurocutaneous disorders, including neurofibromatosis type …
Neurofibromatosis as a gateway to better treatment for a variety of malignancies.
Bakker AC, La Rosa S, Sherman LS, Knight P, Lee H, Pancza P, Nievo M. Bakker AC, et al. Prog Neurobiol. 2017 May;152:149-165. doi: 10.1016/j.pneurobio.2016.01.004. Epub 2016 Feb 5. Prog Neurobiol. 2017. PMID: 26854064 Review.
The neurofibromatoses (NF) are a group of rare genetic disorders that can affect all races equally at an incidence from 1:3000 (NF1) to a log unit lower for NF2 and schwannomatosis. Since the research community is reporting an increasing number of malignant cancers that ca …
The neurofibromatoses (NF) are a group of rare genetic disorders that can affect all races equally at an incidence from 1:3000 (NF1) to a lo …
Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors.
Strowd RE 3rd. Strowd RE 3rd. Curr Treat Options Oncol. 2020 Aug 7;21(10):81. doi: 10.1007/s11864-020-00779-z. Curr Treat Options Oncol. 2020. PMID: 32767156 Review.
Though the majority of nervous system tumors are sporadic, several clinically relevant genetic syndromes are associated with a predisposition to tumors of the central and peripheral nervous system including neurofibromatosis type 1 (NF1), type 2 (NF2), and schwannomatos …
Though the majority of nervous system tumors are sporadic, several clinically relevant genetic syndromes are associated with a predispositio …
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.
Casey D, Demko S, Sinha A, Mishra-Kalyani PS, Shen YL, Khasar S, Goheer MA, Helms WS, Pan L, Xu Y, Fan J, Leong R, Liu J, Yang Y, Windsor K, Ou M, Stephens O, Oh B, Reaman GH, Nair A, Shord SS, Bhatnagar V, Daniels SR, Sickafuse S, Goldberg KB, Theoret MR, Pazdur R, Singh H. Casey D, et al. Clin Cancer Res. 2021 Aug 1;27(15):4142-4146. doi: 10.1158/1078-0432.CCR-20-5032. Epub 2021 Mar 12. Clin Cancer Res. 2021. PMID: 33712511
Approval was based on demonstration of a durable overall response rate per Response Evaluation in Neurofibromatosis and Schwannomatosis criteria and supported by observed clinical improvements in plexiform neurofibroma-related symptoms and functional impairments in …
Approval was based on demonstration of a durable overall response rate per Response Evaluation in Neurofibromatosis and Schwannomatosis …
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
Plotkin SR, Allen J, Dhall G, Campian JL, Clapp DW, Fisher MJ, Jain RK, Tonsgard J, Ullrich NJ, Thomas C, Edwards LJ, Korf B, Packer R, Karajannis MA, Blakeley JO. Plotkin SR, et al. Neuro Oncol. 2023 Aug 3;25(8):1498-1506. doi: 10.1093/neuonc/noad066. Neuro Oncol. 2023. PMID: 37010875 Free PMC article. Clinical Trial.
BACKGROUND: Prospective data on maintenance therapy with bevacizumab for persons with NF2-related schwannomatosis (NF2-SWN) is lacking. In this prospective multicenter phase II study, we evaluated the efficacy, safety, and tolerability of bevacizumab for maintenance therap …
BACKGROUND: Prospective data on maintenance therapy with bevacizumab for persons with NF2-related schwannomatosis (NF2-SWN) is lackin …
Achieving consensus for clinical trials: the REiNS International Collaboration.
Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Widemann BC. Plotkin SR, et al. Neurology. 2013 Nov 19;81(21 Suppl 1):S1-5. doi: 10.1212/01.wnl.0000435743.49414.b6. Neurology. 2013. PMID: 24249801 Free PMC article. Review.
The neurofibromatoses (NF)--including neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis--are related tumor-suppressor syndromes characterized by a predisposition to multiple tumor types and other disease manifestations, which often result in …
The neurofibromatoses (NF)--including neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis--are related t …
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO; Whole Body MRI Committee for the REiNS International Collaboration; REiNS International Collaboration Members 2016. Ahlawat S, et al. Neurology. 2016 Aug 16;87(7 Suppl 1):S31-9. doi: 10.1212/WNL.0000000000002929. Neurology. 2016. PMID: 27527647 Free PMC article.
OBJECTIVES: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosi …
OBJECTIVES: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-M …
42 results